Benign prostatic hyperplasia -Epidemiology Forecast to 2027

Benign prostatic hyperplasia -Epidemiology Forecast to 2027

Category

Pharmaceuticals

Published Date

1st Feb 2018

Pages

50

Choose License

Final Price

DelveInsight's "Benign prostatic hyperplasia (BPH) - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Benign prostatic hyperplasia (BPH) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2027

Benign prostatic hyperplasia (BPH) Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Benign prostatic hyperplasia (BPH) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Benign prostatic hyperplasia (BPH) outlook. It also includes the explanation of changing trends of epidemiology outlining the Benign prostatic hyperplasia (BPH) scenario.

Benign prostatic hyperplasia (BPH) Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Benign prostatic hyperplasia (BPH) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Benign prostatic hyperplasia (BPH) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Benign prostatic hyperplasia (BPH) Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Benign prostatic hyperplasia (BPH)

Key assessments
• Patient Segmentation in Benign prostatic hyperplasia (BPH)
• Benign prostatic hyperplasia (BPH) Risk & Burden
• Factors driving growth in a specific Benign prostatic hyperplasia (BPH) patient population
1. Report Introduction
2. Benign prostatic hyperplasia (BPH) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Benign prostatic hyperplasia (BPH) in 2017
2.2. Patient Share Distribution of Benign prostatic hyperplasia (BPH) in 2027
3. Disease Background and Overview: Benign prostatic hyperplasia (BPH)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Benign prostatic hyperplasia (BPH) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Benign prostatic hyperplasia (BPH) in 7MM – By Countries
5. Epidemiology of Benign prostatic hyperplasia (BPH) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.1.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) *
5.1.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)*
5.1.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.4.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)*
5.4.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)*
5.4.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.5.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)*
5.5.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)*
5.5.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.6.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)*
5.6.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)*
5.6.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.7.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)*
5.7.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)*
5.7.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.8.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)*
5.8.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)*
5.8.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH)
5.9.3. Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH)*
5.9.4. Sex- Specific Cases of the Benign prostatic hyperplasia (BPH)*
5.9.5. Diagnosed Cases of the Benign prostatic hyperplasia (BPH)
6. Unmet Needs of the Benign prostatic hyperplasia (BPH)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific
Table 1: Total Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in 7MM
Table 2: Total Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2027)
Table 4: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2027)*
Table 5: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2027)*
Table 6: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in United States (2016-2027)
Table 7: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2027)
Table 8: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2027) *
Table 9: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2027) *
Table 10: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Germany (2016-2027)
Table 11: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2027)
Table 12: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in France (2016-2027) *
Table 13: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2027) *
Table 14: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in France (2016-2027)
Table 15: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2027)
Table 16: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2027) *
Table 17: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2027) *
Table 18: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Italy (2016-2027)
Table 19: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2027)
Table 20: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2027) *
Table 21: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2027) *
Table 22: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Spain (2016-2027)
Table 23: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2027)
Table 24: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2027) *
Table 25: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2027) *
Table 26: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in UK (2016-2027)
Table 27: Prevalent/Incident Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2027)
Table 28: Sub-Type Specific cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2027) *
Table 29: Sex- Specific Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2027) *
Table 30: Diagnosed Cases of the Benign prostatic hyperplasia (BPH) in Japan (2016-2027)

Get Free Sample

You can get a FREE sample of any report. Just click the "Free Sample" link.

Explore Latest Reports

If you have any special requirement or looking for more discounts, Kindly contact our sales team

Contact Us